Myrcludex B

Drug Profile

Myrcludex B

Alternative Names: Myrcludex-B

Latest Information Update: 29 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator INSERM; University of Heidelberg; Vision7
  • Developer Hepatera; MYR GmbH; Vision7
  • Class Antivirals; Lipopeptides
  • Mechanism of Action Cell surface receptor antagonists; Sodium-bile acid cotransporter-inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 25 May 2017 Myrcludex B receives Priority Medicine (PRIME) status for Hepatitis D in European Union
  • 04 Apr 2017 Hepatera and MYR completes enrolment in the phase IIb MYR-202 trial for Hepatitis B and Hepatitis D in Russia and Germany
  • 04 Apr 2017 Hepatera and MYR completes enrolment in the phase IIb MYR-203 trial for Hepatitis B and Hepatitis D in Russia (NCT02888106)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top